Overview

A Safety and Efficacy Study of MSI-1256F (Squalamine Lactate) To Treat "Wet" Age-Related Macular Degeneration

Status:
Terminated

Trial end date:
2007-05-01

Target enrollment:
0

Participant gender:
All

Summary

Age-Related Macular Degeneration (AMD) is a degenerative eye disease of the retina that causes a progressive loss of central vision. AMD is the leading cause of legal blindness among adults age 50 or older in the Western world. AMD presents in two different types - "dry" and the more severe "wet" form. Wet AMD is caused by the growth of abnormal blood vessels in the macula. Squalamine lactate is an investigational drug that may prevent the growth of these abnormal blood vessels. This study will test the safety and efficacy of Squalamine in the treatment of AMD.

Phase:

Phase 2

Accepts Healthy Volunteers?

Details

Lead Sponsor:

Genaera Corporation

Treatments:

Squalamine

Criteria

Inclusion Criteria:

- Patients with a diagnosis of "wet" age-related macular degeneration

Exclusion Criteria:

- Prior treatment of "wet" age-related macular degeneration in the affected eye in the
past 3 months